Hong Kong Stock Movement: MIRXES-B fell 12.72%, with no significant news but showing volatility. What is driving the market sentiment?

Hong Kong Stock Movement MIRXES-B, down 12.72%, with no significant news recently. Trading is active, and capital flows are evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Stocks with High Trading Volume in the Industry Sihuan Pharmaceutical down 6.10%. Based on recent news, On March 30, Sihuan Pharmaceutical union members voted overwhelmingly in favor of a strike, with a voting approval rate of 95.52% and a participation rate of 95.38%. This news raised market concerns, leading to a decline in stock price. On March 31, Sihuan Pharmaceutical announced it would distribute a special dividend through a physical distribution method, distributing all shares of Mandi held by the company to eligible shareholders. This move was interpreted by the market as a strategic adjustment by the company, increasing uncertainty and affecting the stock price. On March 30, Sihuan Pharmaceutical released its 2025 performance report. Despite significant growth in revenue and profit, concerns about future profitability remain, putting pressure on the stock price. The biotechnology industry has been volatile recently, and investors should be cautious. Innovent Biologics down 1.68%. Based on recent key news: On March 30, Innovent Biologics announced its 2025 performance, with revenue increasing by 38.4% year-on-year, but the net profit forecast for 2026 was lowered by 15.3%. The performance met expectations, but the downward revision of future profit forecasts puts pressure on the stock price. Source: Zhitong Finance On March 30, Innovent Biologics granted stock options and restricted shares, with an exercise price of HKD 86.1 per share. This move may raise market concerns about equity dilution, affecting stock performance. Source: Zhitong Finance On March 30, Innovent Biologics' MaShidu peptide performed excellently in clinical research, showing potential in the treatment of obesity and diabetes. Despite positive R&D progress, market concerns about short-term profitability remain. Source: Times Online. The innovative drug industry faces pressure from medical insurance and international challenges. Kangfang Biologics down 2.25%. Based on recent key news: On March 30, Kangfang Biologics' revenue did not meet expectations, mainly due to limitations on indications. The indications for Cadonilimab and Ivosidenib did not expand as expected, leading to uncertainty about the realization of 2026 performance. Kangfang Biologics' stock price was thus under pressure. On March 30, Kangfang Biologics reported a loss of 1.141 billion yuan in 2025, a year-on-year increase of 56%. The loss mainly stemmed from changes in stock value and increased R&D investment. Despite ample cash reserves, the market doubts its future profitability. On March 30, several innovative projects of Kangfang Biologics require substantial R&D expenses, increasing the risks faced by the company. Despite having a leading advantage, competitors' pursuit makes the market cautious about its future performance. The pharmaceutical industry shows strong short-term performance, with significant capital inflows. Stocks with High Market Capitalization in the Industry BeiGene rose by 0.70%. Based on recent news, On March 30, the National Medical Products Administration announced that the total value of foreign licensing transactions for innovative drugs in China in the first quarter of 2026 exceeded USD 60 billion, approaching half of the total for the entire year of 2025. As a leading company in the field of innovative drugs, BeiGene has participated in multiple foreign licensing transactions, driving up its stock price. On March 30, Industrial Securities stated that the global competitiveness of China's innovative drugs continues to strengthen, with ongoing international expansion and unchanged industrial logic for commercial profitability. As a leading enterprise in the research and development of innovative oncology drugs, BeiGene benefits from this trend, leading to an increase in its stock price. On March 30, Kaiyuan Securities mentioned that the recovery of global biopharmaceutical investment and financing in 2025, along with the increased activity in innovative drug research and development, has driven the CXO industry demand from recovery to a substantial expansion phase. As an important part of the innovative drug industry chain, BeiGene benefits from the overall positive trend in the industry, resulting in an increase in its stock price. The innovative drug sector has significant development potential, and the industry as a whole is improving